Stock 600252 GUANGXI WUZHOU ZHONGHENG GROUP CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Guangxi Wuzhou Zhongheng Group Co.,Ltd

Equities

600252

CNE0000015F9

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
2.35 CNY +2.17% Intraday chart for Guangxi Wuzhou Zhongheng Group Co.,Ltd +4.91% -6.37%
Apr. 29 Guangxi Wuzhou Zhongheng Group Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 17 Guangxi Wuzhou Zhongheng Group Co.,Ltd commences an Equity Buyback for CNY 200 million worth of its shares, under the authorization approved on March 28, 2024. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 8,931 11,232 10,515 13,221 9,104 8,647
Enterprise Value (EV) 1 5,771 8,599 8,847 10,342 6,868 6,343
P/E ratio 14.6 x 15.2 x 19.2 x 43.1 x 114 x 102 x
Yield 2.33% 1.84% 2.8% 0.7% 0.38% 0.4%
Capitalization / Revenue 2.71 x 2.94 x 2.86 x 4.18 x 3.35 x 2.79 x
EV / Revenue 1.75 x 2.25 x 2.41 x 3.27 x 2.53 x 2.05 x
EV / EBITDA 9.17 x 12 x 17.6 x 41.7 x 42 x 35.1 x
EV / FCF 19.3 x 30.2 x -16.8 x -11.8 x -26.8 x -121 x
FCF Yield 5.19% 3.31% -5.94% -8.5% -3.73% -0.83%
Price to Book 1.51 x 1.75 x 1.54 x 2 x 1.4 x 1.31 x
Nbr of stocks (in thousands) 3,475,107 3,445,387 3,425,209 3,425,209 3,461,584 3,445,116
Reference price 2 2.570 3.260 3.070 3.860 2.630 2.510
Announcement Date 4/2/19 3/25/20 3/30/21 4/17/22 3/28/23 3/29/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 3,299 3,814 3,676 3,162 2,714 3,097
EBITDA 1 629.3 718.9 502.9 247.7 163.7 180.6
EBIT 1 538.3 622 328 65.39 -15.87 -1.599
Operating Margin 16.32% 16.31% 8.92% 2.07% -0.58% -0.05%
Earnings before Tax (EBT) 1 704.9 903.6 321.3 231.5 63.81 82.68
Net income 1 613.4 745 562.8 306.9 79.03 84.31
Net margin 18.59% 19.53% 15.31% 9.71% 2.91% 2.72%
EPS 2 0.1765 0.2150 0.1600 0.0896 0.0231 0.0246
Free Cash Flow 1 299.6 284.7 -525.7 -879.4 -256.1 -52.41
FCF margin 9.08% 7.47% -14.3% -27.81% -9.44% -1.69%
FCF Conversion (EBITDA) 47.62% 39.61% - - - -
FCF Conversion (Net income) 48.85% 38.22% - - - -
Dividend per Share 2 0.0600 0.0600 0.0860 0.0270 0.0100 0.0100
Announcement Date 4/2/19 3/25/20 3/30/21 4/17/22 3/28/23 3/29/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3,160 2,633 1,668 2,879 2,236 2,305
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 300 285 -526 -879 -256 -52.4
ROE (net income / shareholders' equity) 10.6% 12.1% 3.23% 2.05% 0.15% 0.37%
ROA (Net income/ Total Assets) 4.77% 5.16% 2.07% 0.34% -0.08% -0.01%
Assets 1 12,856 14,443 27,191 89,637 -94,190 -991,868
Book Value Per Share 2 1.710 1.870 2.000 1.930 1.880 1.910
Cash Flow per Share 2 0.6800 0.8000 1.040 0.9000 1.020 0.8600
Capex 1 211 160 167 297 202 167
Capex / Sales 6.39% 4.2% 4.54% 9.4% 7.43% 5.39%
Announcement Date 4/2/19 3/25/20 3/30/21 4/17/22 3/28/23 3/29/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
GUANGXI WUZHOU ZHONGHENG GROUP CO.,LTD Stock Guangxi Wuzhou Zhongheng Group Co.,Ltd
-6.37% 1.12B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.70% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.42% 234B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-10.10% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 600252 Stock
  4. Financials Guangxi Wuzhou Zhongheng Group Co.,Ltd